Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEV-53408 in Non-Segmental Vitiligo
NCT07920211Phase 3Not yet recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Nov 2026
- Primary completion
- Sep 2030
01
Overview
Phase 3, randomised, double-blind trial of TEV-53408 in Vitiligo (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Proportion of Participants Achieving a >=75% Reduction in Facial Vitiligo Area Scoring Index at 48 weeks and Proportion of Participants Achieving a >=50% Reduction in Total Vitiligo Area Scoring Index at 48 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
TEV-53408
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT07920211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07920211.